# OnCo record all-paediatric-standard-risk (cancer). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)". Whole corpus: https://onco.cc/api/v1/onco.nt
@prefix schema: <https://schema.org/> .
@prefix onco: <https://onco.cc/ns#> .
@prefix xsd: <http://www.w3.org/2001/XMLSchema#> .

<https://onco.cc/cancers/all-paediatric-standard-risk/>
  a schema:MedicalCondition ;
  onco:kind "cancer" ;
  schema:identifier "all-paediatric-standard-risk" ;
  schema:name "Standard-risk B-cell acute lymphoblastic leukaemia in children"@en ;
  schema:alternateName "NCI standard-risk B-ALL"@en, "Average-risk childhood ALL"@en, "Low-risk childhood ALL"@en ;
  schema:description "Standard-risk acute lymphoblastic leukaemia is the commonest and most curable childhood cancer: a child aged one to nine with a modest white cell count and favourable genetics. Two to three years of chemotherapy cures about nine in ten, and adding the immune drug blinatumomab to the chemotherapy in the AALL1731 trial cut relapses further."@en ;
  schema:url <https://onco.cc/cancers/all-paediatric-standard-risk/> ;
  schema:dateModified "2026-09-17"^^xsd:date ;
  schema:sameAs <https://en.wikipedia.org/wiki/Acute_lymphoblastic_leukemia> ;
  schema:citation <https://en.wikipedia.org/wiki/Acute_lymphoblastic_leukemia>, <https://www.cancer.gov/types/leukemia/hp/child-all-treatment-pdq> ;
  onco:tag "subtype-page", "paediatric" ;
  onco:related <https://onco.cc/cancers/all-paediatric-high-risk/>, <https://onco.cc/cancers/all-paediatric-relapsed/> ;
  onco:technologies <https://onco.cc/technologies/flow-cytometry-mrd/>, <https://onco.cc/technologies/t-cell-engager/> ;
  onco:targets <https://onco.cc/targets/cd19/> ;
  onco:institutions <https://onco.cc/institutions/childrens-oncology-group/>, <https://onco.cc/institutions/st-jude/> ;
  onco:terms <https://onco.cc/terms/mrd/>, <https://onco.cc/terms/efs/>, <https://onco.cc/terms/b-all-cytogenetic-risk/> ;
  onco:keyPapers <https://onco.cc/key-papers/paper-aall1731-blinatumomab-children-nejm-2025/> ;
  onco:pipeline <https://onco.cc/drugs/blinatumomab/>, <https://onco.cc/trials/aall1731/>, <https://onco.cc/technologies/ngs-mrd-clonoseq/>, <https://onco.cc/pairings/blinatumomab-frontline-consolidation/>, <https://onco.cc/ideas/idea-tr2-paediatric-combo-prea/> ;
  onco:standardOfCare <https://onco.cc/drugs/vincristine/>, <https://onco.cc/drugs/dexamethasone/>, <https://onco.cc/drugs/asparaginase/>, <https://onco.cc/drugs/methotrexate/>, <https://onco.cc/technologies/flow-cytometry-mrd/>, <https://onco.cc/drugs/cyclophosphamide/>, <https://onco.cc/drugs/cytarabine/>, <https://onco.cc/drugs/mercaptopurine/>, <https://onco.cc/drugs/methotrexate/>, <https://onco.cc/drugs/blinatumomab/>, <https://onco.cc/trials/aall1731/>, <https://onco.cc/pairings/blinatumomab-frontline-consolidation/>, <https://onco.cc/drugs/vincristine/>, <https://onco.cc/drugs/dexamethasone/>, <https://onco.cc/drugs/doxorubicin/>, <https://onco.cc/drugs/cyclophosphamide/>, <https://onco.cc/drugs/thioguanine/>, <https://onco.cc/drugs/mercaptopurine/>, <https://onco.cc/drugs/methotrexate/>, <https://onco.cc/drugs/blinatumomab/>, <https://onco.cc/drugs/tisagenlecleucel/>, <https://onco.cc/drugs/inotuzumab-ozogamicin/>, <https://onco.cc/cancers/all-paediatric-relapsed/> .